Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(23):1878-1879; doi:10.1093/jnci/92.23.1878
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 23, 1878-1879, December 6, 2000
© 2000 Oxford University Press

NEWS

Targeted Cancer Therapies Attempt to Hit the Bull’s-eye

Mike Miller

Flooding the body with chemotherapy drugs in hopes of knocking out an isolated tumor has been one modus operandi of treating cancer for many decades. But the side effects of this kind of blanket coverage can sometimes be as debilitating as the disease itself. For that reason, researchers are looking at better ways to target therapies to treat cancer and reduce unwanted side effects.

Difficult to Target

According to Esmail Tabibi, Ph.D., of the Pharmaceutical Resources Branch at the National Cancer Institute, biological heterogeneity of tumors, unidentified targets, and other factors make it difficult in most adult cases to deliver the . . . [Full Text of this Article]

Unique Target

Best Known Targeted Therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?